Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.76 |
| ▸ | RAB9A | P51151 | 8/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.76 |
| ▸ | MAOA | P21397 | 5/20 | 0.69 |
| ▸ | MAOB | P27338 | 5/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3053780 | 0.87 | SMN1; SMN2 (0.62) | NPC1RAB9AMAPTALDH1A1HPGD | |
| SCHEMBL31156451 | 0.86 | NPC1 (1.00) | NPC1RAB9AMAPTMAOAMAOB | |
| SCHEMBL4761937 | 0.86 | NPC1 (1.00) | NPC1RAB9AMAPTMAOAMAOB | |
| SCHEMBL5713502 | 0.81 | NPC1 (0.72) | NPC1RAB9AMAPTALDH1A1HPGD | |
| SCHEMBL5818769 | 0.80 | NPC1 (1.00) | NPC1RAB9AMAPTALDH1A1HPGD | |
| SCHEMBL31668680 | 0.79 | MAOB (0.88) | NPC1RAB9AMAPTMAOAMAOB | |
| SCHEMBL3054874 | 0.77 | SMN1; SMN2 (0.62) | NPC1RAB9AMAPTALDH1A1HPGD | |
| SCHEMBL6166855 | 0.76 | MAOA (0.73) | NPC1RAB9AMAPTMAOAMAOB | |
| SCHEMBL4347943 | 0.76 | NPC1 (0.69) | NPC1RAB9AMAPTMAOAMAOB | |
| N-(Phenylcarbamothioyl)Benzamide SCHEMBL2341910 | 0.75 | EPHX1 (1.00) | NPC1RAB9AALDH1A1HPGDALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3708164-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3708164-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3139919-B1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS INC (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3139919-B1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS INC (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10155728-B2 | Compounds for treatment of cancer | GTX INC. (US) | 2018-12-18 | — | — | US | disclosed |
| US-9981915-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180118693-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| EP-3139919-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Gtx, Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20170057930-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057930-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-7375219-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2008-05-20 | — | — | US | disclosed |
| US-7375219-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2008-05-20 | — | — | US | disclosed |
| EP-1883451-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007063418-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007063418-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-06-07 | — | — | WO | disclosed |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-16 | — | — | US | disclosed |
| EP-0619805-B1 | 5-(HETERO- OR CARBOCYCLYLAMINO)-INDOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS 5-HT1 AGONISTS | PFIZER (US) | 2000-03-15 | — | — | EP | disclosed |
| US-5639752-A | SEROTONIN AGONIST | PFIZER INC (US) | 1997-06-17 | — | — | US | disclosed |
| EP-0619805-A1 | INDOLE DERIVATIVES | PFIZER HOSPITAL PRODUCTS, INC. (US) | 1994-10-19 | — | — | EP | disclosed |
| WO-1993011106-A1 | INDOLE DERIVATIVES | PFIZER, INC. (US) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155728-B2 | Compounds for treatment of cancer | TP53, TUBB1, TUBB6 | NPC1 269/4885RAB9A 2957/4885MAPT 699/4885 |
| US-20180118693-A1 | COMPOUNDS FOR TREATMENT OF CANCER | TP53, TUBB1, TUBB6 | NPC1 269/4885RAB9A 2957/4885MAPT 699/4885 |
| US-20170057930-A1 | COMPOUNDS FOR TREATMENT OF CANCER | TP53, TUBB1, TUBB6 | NPC1 269/4885RAB9A 2957/4885MAPT 699/4885 |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NOS2, NOS1, NOS3 | NPC1 906/4885RAB9A 3399/4885MAPT 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.